For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Sarepta Therapeutics, Inc.

USPTO Granted Patents = 122

CIPO Patents = 11

EPO Patents = 41

Trademarks = 44

Forward Citations = 1,691

Loading Chart...

Loading Chart...

64 inventors (with patents filed for the assignee):

Gunnar J Hanson (39 out of 181 patents)

Patrick L Iversen (36 out of 95 patents)

Dwight D Weller (27 out of 61 patents)

4. Ryszard M Kole (23 out of 29 patents)

5. Richard Keith Bestwick (17 out of 36 patents)

6. Ming Zhou (12 out of 32 patents)

7. Frederick Joseph Schnell (10 out of 10 patents)

8. Marco A Passini (10 out of 25 patents)

9. David A Stein (9 out of 24 patents)

10. Baozhong Cai (8 out of 8 patents)

11. Bao Zhong Cai (8 out of 9 patents)

12. Dan V Mourich (8 out of 11 patents)

13. Mitchell Martini (7 out of 7 patents)

14. Ross Shimabuku (7 out of 7 patents)

15. Katie Thomas (7 out of 7 patents)

Core Competencies:

Adeno-Associated Virus

Oligonucleotide Analogues

Exon Skipping

Antisense Oligomers

Peptide Oligonucleotide Conjugates

Muscular Dystrophy

Chimeric Peptides

Phosphorodiamidate Morpholino Oligomers

Cell-Penetrating Peptides

Rett Syndrome

Myotonic Dystrophy

Expanded Repeat Diseases

122 patents: Sort by Forward Citations

1. 12391745 - Adeno-associated virus antibodies and fragments thereof (2025-08-19),

2. 12377150 - Exon skipping oligomer conjugates for muscular dystrophy (2025-08-05),

3. 12370261 - Chimeric peptides for antisense delivery (2025-07-29),

4. 12297219 - Phosphorodiamidate morpholino oligomers (2025-05-13),

5. 12286630 - Treatment methods for muscular dystrophy (2025-04-29),

6. 12258362 - Processes for preparing phosphorodiamidate morpholino oligomers (2025-03-25),

7. 12239715 - Peptide oligonucleotide conjugates (2025-03-04),

8. 12168059 - Trimeric peptides for antisense delivery (2024-12-17),

9. 12139709 - Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene (2024-11-12),

10. 12138312 - Cell-penetrating peptides for antisense delivery (2024-11-12),

11. 12121532 - Modified antisense oligomers for exon inclusion in spinal muscular atrophy (2024-10-22),

12. 12104163 - Adeno-associated virus vectors for treatment of Rett syndrome (2024-10-01),

13. 11932851 - Exon skipping compositions for treating muscular dystrophy (2024-03-19),

14. 11925675 - Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy (2024-03-12),

15. 11911403 - Antisense-induced exon exclusion in type VII collagen (2024-02-27),

Sarepta Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of precision genetic medicines for rare neuromuscular diseases. With a strong commitment to advancing scientific research and improving patient lives, Sarepta is driven to deliver innovative therapies that address the underlying causes of these debilitating conditions. Through its dedication to precision medicine, Sarepta aims to transform the lives of patients suffering from rare genetic diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

122 Patents

#22 in Cambridge, MA

#173 in Massachusetts

#3,045 in US

#6,355 in the World

Cambridge, MA, United States of America

Sarepta Therapeutics, Inc.

Forward Citations = 1,691

64 inventors:

Gunnar J Hanson (39 out of 181 patents)

Patrick L Iversen (36 out of 95 patents)

Dwight D Weller (27 out of 61 patents)

4. Ryszard M Kole (23 out of 29 patents)

5. Richard Keith Bestwick (17 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…